Your browser doesn't support javascript.
loading
Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease in the U.S. Real-World Settings.
Hur, Peter; Yi, Esther; Ionescu-Ittu, Raluca; Manceur, Ameur M; Lomax, Kathleen G; Cammarota, Jordan; Xie, Jipan; Gautam, Raju; Nakasato, Priscila; Sanghera, Navneet; Kim, Nina; Grom, Alexei A.
Afiliación
  • Hur P; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Yi E; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Ionescu-Ittu R; Analysis Group, Inc, Montreal, QC, Canada.
  • Manceur AM; Analysis Group, Inc, Montreal, QC, Canada.
  • Lomax KG; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Cammarota J; Analysis Group, Inc, Washington, DC, USA.
  • Xie J; Analysis Group, Inc, Los Angeles, CA, USA.
  • Gautam R; Novartis Healthcare Pvt. Ltd, Hyderabad, India.
  • Nakasato P; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Sanghera N; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Kim N; Baylor Scott and White Medical Center-Temple, Temple, TX, USA.
  • Grom AA; The University of Texas at Austin, Austin, TX, USA.
Rheumatol Ther ; 9(1): 265-283, 2022 Feb.
Article en En | MEDLINE | ID: mdl-34874547
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Rheumatol Ther Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Rheumatol Ther Año: 2022 Tipo del documento: Article